Company news

Nasus Pharma Ltd. news in 2025

Nasus Pharma Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Nasus Pharma CEO Issues 2025 Letter to Shareholders

December 22, 2025

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

November 20, 2025

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

November 18, 2025

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

November 6, 2025

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

October 8, 2025

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

August 26, 2025

Nasus Pharma Announces Closing of Initial Public Offering

August 14, 2025

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

August 13, 2025

Decks in 2025